Siltuximab for antibody-mediated rejection after lung transplant
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This trial tests a drug called siltuximab to see if it can help treat a type of lung rejection called antibody-mediated rejection (AMR) in people who have had a lung transplant. You may be eligible if you are currently hospitalized for AMR and are already planning to receive standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have had a single or double lung transplant.
- You have been diagnosed with antibody-mediated rejection (AMR) and are being treated with medications like Carfilzomib or anti-thymocyte globulin.
- You are currently in the hospital for your AMR treatment.
- You have specific antibodies (DSA) against the donor lung with a level over 1000 MFI.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if siltuximab can prevent severe immune-related side effects when patients restart immunotherapy (anti-PD-1/PD-L1) after previous severe side effects. It aims to make rechallenge safer for people with advanced cancer.
This trial tests a new drug, siplizumab, to see if it helps the body accept a donated kidney better than a standard treatment. It is for people receiving a kidney transplant from a living or deceased donor.
This study tests whether the drug tocilizumab can help prevent your body from rejecting a new lung after transplant. It might help improve the success of your transplant by reducing immune system activity.
This trial tests if adding silymarin (a milk thistle extract) to standard anti-rejection medicines helps protect the new kidney from damage. It may improve how well the transplanted kidney works over time.
This trial tests whether the drug Belumosudil can help prevent chronic lung rejection in people who recently had a lung transplant and showed signs of early rejection. It may improve long-term lung health.
This trial tests whether giving siltuximab before epcoritamab can help prevent or reduce cytokine release syndrome (a possible side effect where the immune system overreacts). It is for people with certain types of non-Hodgkin lymphoma that have not responded well to at least two prior treatments.
Hear when a new Antibody Mediated Rejection of Lung Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.